Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...

People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most ...

The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition ...

A ground-breaking method for predicting bowel cancer among those at higher risk has achieved over 90% accuracy, according to ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

As part of their research, scientists developed an algorithm that calculates a person's risk of future bowel cancer based on ...

Bowel Cancer UK has revealed that around half of all bowel cancers could be prevented by having a healthier lifestyle.